Close

Malvern Panalytical and Concept Life Sciences announce integration

Subscribe

- Never miss a story with notifications

- Gain full access to our premium content

- Browse free from any location or device.

Media Packs

Expand Your Reach With Our Customized Solutions Empowering Your Campaigns To Maximize Your Reach & Drive Real Results!

– Access the Media Pack Now

– Book a Conference Call

– Leave Message for Us to Get Back

Related stories

How Language Barriers Impact Non-Native English Speakers in Healthcare

Language barriers create significant challenges for non-native English speakers...

FDA Approval of AMVUTTRA for ATTR Amyloidosis

Alnylam Pharmaceuticals, Inc., a global leader in RNAi therapeutics,...

Rina-S Shows Promise in Advanced Ovarian Cancer

Genmab has reported encouraging findings from the Phase 2...

Pharma Support Powers Sofinnova Biotech Acceleration Fund

Sofinnova Partners Closes €165M Biotech Acceleration Fund with Strong...

Malvern Panalytical, manufacturer of analytical systems, and Concept Life Sciences (Cheshire, UK), a contract research organization, have today announced a full business integration. The integration will expand the existing analytical instrument and service relationship (Amplify Analytics) to include the Chemistry and Biology services of CLS. Both entities are operating businesses within the Spectris plc Group.

Mark Fleiner, President, Malvern Panalytical, expressed excitement about the opportunities presented by the integration: “Everyone at Malvern Panalytical is deeply committed to supporting our customers in delivering the pharmaceutical and agrochemical products needed to improve our health and quality of life. During this pandemic, we’ve already seen how, together with our customers, we can play a small but important role in enabling the development of vital medicines and treatments which can make a big contribution to the health of the world. We are all delighted to significantly build on our capability to achieve this with the passion, expertise and commitment of the combined Malvern Panalytical and Concept Life Sciences teams.”

The integration builds on the companies’ 2020 launch of Amplify Analytics – a range of flexible services designed to help pharmaceutical organizations identify new drug candidates and de-risk the process of developing robust formulations. The success of the collaboration has been demonstrated in the significant value delivered to clients, providing the insight needed to bring pharmaceutical products to market quickly and efficiently.

Although the union of the two businesses will bring new approaches to client support, the strong commitment of CLS to its existing clients remains unchanged. Mark Carnegie-Brown, President of CLS, confirmed: “We have made sure that there is a seamless transition to the Malvern Panalytical platform for all our clients, free from changes to key contacts and existing service and confidentiality agreements. Our clients should not notice any changes to how we interact with them, but they will see expanded access to all capabilities and expertise across Concept Life Sciences and Malvern Panalytical. Our excited and enthused combined teams are eager to explore the unique opportunities delivered by our integration.”

About Malvern Panalytical
When you make the invisible visible, the impossible is possible. Our analytical instruments and solutions help our customers to create a better world. Through chemical, physical and structural analysis of materials, they improve everything from the energies that power us and the materials we build with, to the medicines that cure us and the foods we enjoy. We partner with many of the world’s biggest companies, universities and research organizations. They value us not only for the power of our solutions, but also for the depth of our expertise, collaboration and integrity. We are, with over 2,200 people worldwide part of Spectris plc, the world-leading precision
measurements Group.

About Concept Life Sciences
Concept Life Sciences is a contract research organization working to solve complex human health challenges in the pharmaceutical, biotechnology, agrochemical, chemical and food industry. We address these through continuous innovation, exceptional science and the
highest customer service. We accelerate our customers’ discovery and development workflows and ensure product support through the application of our expertise to their challenges. We supply a wide range of services, from initial discovery through to development and API manufacture for clinical trials. With over 250 employees, we serve the world, and we are part of Spectris plc, the world-
leading precision measurements group.

Latest stories

Related stories

How Language Barriers Impact Non-Native English Speakers in Healthcare

Language barriers create significant challenges for non-native English speakers...

FDA Approval of AMVUTTRA for ATTR Amyloidosis

Alnylam Pharmaceuticals, Inc., a global leader in RNAi therapeutics,...

Rina-S Shows Promise in Advanced Ovarian Cancer

Genmab has reported encouraging findings from the Phase 2...

Pharma Support Powers Sofinnova Biotech Acceleration Fund

Sofinnova Partners Closes €165M Biotech Acceleration Fund with Strong...

Subscribe

- Never miss a story with notifications

- Gain full access to our premium content

- Browse free from any location or device.

Media Packs

Expand Your Reach With Our Customized Solutions Empowering Your Campaigns To Maximize Your Reach & Drive Real Results!

– Access the Media Pack Now

– Book a Conference Call

– Leave Message for Us to Get Back